Off-Label Communication and What May Be Said
The same information can be lawful from one speaker and an offense from another. What separates them is not accuracy but who is speaking, to whom, and whether the speech establishes an intended use the product was never approved for.
The rule in short
A licensed practitioner may prescribe an approved product outside its labeling. A manufacturer that promotes an unapproved use faces misbranding and unapproved product theories, because under 21 CFR 201.128 intended use may be shown by labeling, advertising and representatives' statements. Narrow pathways permit responses to unsolicited requests, qualifying reprints, communications consistent with labeling, and economic information to payors.
Off-label use is lawful, common and in some specialties unavoidable. Off-label promotion is a federal offense. Both statements are true at once, and the reason is that the statute regulates products and the persons who market them, not the judgment of the clinician who writes the prescription.
The prescriber's position
The statute contains an explicit disclaimer of authority over the practice of medicine, providing that nothing in it limits or interferes with the authority of a health care practitioner to prescribe or administer a legally marketed device for any condition within a legitimate practitioner-patient relationship. The same principle is applied to drugs in practice: the agency approves products and labeling, and it does not license or discipline prescribers.
Off-label use is not marginal. In oncology, pediatrics and psychiatry it is routine, because approved labeling reflects the studies a sponsor chose to run rather than the full range of clinical situations. A pediatric population may have no approved option at all, and a practitioner extrapolating from adult data is doing what the field expects. The regulatory system tolerates this precisely because the alternative would be to leave those patients untreated.
The practitioner's exposure lies elsewhere. Malpractice standards, institutional policy, payer coverage rules and consent obligations all bear on an off-label decision, and none of them come from the federal statute. A physician prescribing off-label is on solid regulatory ground and may still be on difficult ground in every other respect.
Why the manufacturer's position differs
A drug or device is approved for particular conditions of use, and the labeling states them. If a manufacturer's conduct establishes that the product is intended for a different use, then as to that use the product has no approval and its labeling lacks adequate directions. That is the structure of the misbranding theory, and it is why promotional speech is legally consequential rather than merely regulated.
There is a second theory that does not depend on speech at all. Where a firm knows that its product is being used for an unapproved purpose and its conduct is directed at that use, the surrounding circumstances of distribution can establish the intended use. Sales targeting, sample placement, distribution patterns and the design of a compensation plan have all been used as evidence, and none of them involves anyone saying anything about the unapproved use.
The intended use regulation makes the connection explicit. Objective intent may be shown by labeling claims, advertising matter, or oral or written statements by the manufacturer or its representatives, and by the circumstances surrounding distribution. Statements are evidence, not the offense itself, but in most enforcement files the statements are the entire evidentiary basis.
Several courts have concluded that truthful, non-misleading speech about a lawful off-label use cannot by itself be criminalized as misbranding, reasoning that the speech is evidence of intent rather than conduct. The agency has not accepted that position across the board, and the decisions do not cover every circuit or every theory. Anyone told that off-label promotion is now permitted, or that the prohibition is unchanged, is hearing one side of a question that has not been settled.
The pathways that are recognized
Several categories of communication are treated as outside promotion, each on stated conditions. The first is a response to an unsolicited request. Where a health care professional asks about an unapproved use without prompting, a company may respond privately to that requester with truthful, balanced, non-misleading and scientific information, delivered by personnel independent of sales and marketing, and the response should be tailored to what was asked.
The second is distribution of scientific and medical publications. Reprints of peer-reviewed articles and clinical practice guidelines may be distributed subject to conditions: the publication should be unabridged, not funded or written in a way that undermines its independence, accompanied by a disclosure that the use is not approved, and physically separate from promotional material.
The third is communication consistent with the approved labeling, which permits statements that go beyond the literal text but remain within what the labeling supports. The fourth is health care economic information provided to payors and formulary committees, which the statute treats specially where the information relates to an approved indication and is based on competent and reliable scientific evidence.
| Communication | Treated as promotion? | Conditions that matter | Principal risk |
|---|---|---|---|
| Sales call describing an unapproved use | Yes | None available | Misbranding and unapproved product theories |
| Private response to an unsolicited request | No, if genuinely unsolicited | Non-promotional personnel, tailored, balanced, documented | Requests that were in fact prompted by the sales force |
| Reprint of a peer-reviewed article | No, on conditions | Unabridged, independent, disclosed, separated from promotion | Selective distribution of favorable literature only |
| Statement consistent with approved labeling | No | Supported by the labeling and by adequate evidence | Drifting past what the labeling actually supports |
| Economic information to a payor | No, within the statutory provision | Approved indication, competent and reliable evidence, payor audience | Delivery to prescribers rather than payors |
| Company-funded speaker program | Depends entirely on content and control | Independence, content review, attendee selection, payments | Serves as the central evidence in most enforcement files |
Where the enforcement actually comes from
The largest exposure in this area has rarely been a straightforward misbranding prosecution. It has come through the theory that promotion for an unapproved use caused claims for reimbursement that were not payable, which converts a labeling issue into a false claims case with treble damages and per-claim penalties. The elements of that theory are set out in express and implied certification and what makes a claim false, and the mechanics by which such cases begin are described in filing a qui tam complaint under seal.
That connection explains the shape of most compliance programs in the industry: they are built around what sales personnel say, what speaker programs contain, how requests are logged, and how payments to prescribers are documented, because those are the records a relator's counsel will read. The financial consequences of losing are described in damages, trebling and per-claim penalties.
The boundary itself is set by the approved labeling, which is why any communications review begins with the document described in required labeling content and how it is changed. Where a company wants to say something the labeling does not support, the orthodox answer is to generate the evidence and change the labeling through the process in the application and its review cycle, which is slower and considerably safer.
Points to carry away
- Prescribing outside the labeling is a practice of medicine question, not a marketing violation.
- Intended use may be established by statements of a manufacturer's representatives.
- Promotion of an unapproved use supports misbranding and unapproved product theories.
- Responses to genuinely unsolicited requests are treated differently from proactive promotion.
- Health care economic information to payors has a statutory safe harbor with conditions.
- Whether truthful speech alone can support a prosecution remains unsettled.
Questions readers ask
Does the prohibition reach conversations with investors?
It can, though the analysis runs through a different door. Statements about a product's likely benefit in an unapproved use, made to investors, are evidence of intended use like any other statement by the company, and they are also securities disclosures subject to their own accuracy requirements. Companies frequently discuss pipeline programs without difficulty, and the difference lies in framing: describing what a trial is testing is not the same as describing what the marketed product does. Enforcement has drawn on earnings calls and investor decks as evidence.
Are medical science liaisons treated as sales personnel?
Not automatically, but the label does not settle it. The distinction that matters is functional: whether the person's role, reporting line, incentives and actual conduct are scientific rather than promotional. Where liaisons are compensated on territory sales, dispatched by sales representatives to specific accounts, or used to deliver messages the sales force cannot, the separation is a form rather than a fact. Companies that rely on the distinction usually document reporting lines, compensation structures and request-logging practices for exactly this reason.
Can a company correct misinformation about its product circulating publicly?
The agency has described a route for a firm to respond to independent third-party misinformation about its own product, including where the correction touches an unapproved use. The response is expected to be limited to the specific misinformation, tailored and non-promotional in tone and presentation, accurate, and directed to the audience that received the original statement. It is a narrow allowance rather than a general license to enter public debate, and using a correction as an opening for broader promotion defeats it.
Sources
- Cornell Legal Information Institute — 21 U.S.C. 396, Practice of MedicineThe statute's disclaimer of authority over a practitioner's prescribing decisions.
- Cornell Legal Information Institute — 21 U.S.C. 352, Misbranded Drugs and DevicesThe misbranding grounds and the health care economic information provision.
- Cornell Legal Information Institute — 21 U.S.C. 331, Prohibited ActsIntroduction of a misbranded or unapproved article into interstate commerce.
- Cornell Legal Information Institute — 21 U.S.C. 355, New DrugsThe requirement of an effective approval for the intended conditions of use.
- eCFR — 21 CFR 201.128, Meaning of Intended UsesHow objective intent is established, including through representatives' statements.
- eCFR — 21 CFR 202.1, Prescription Drug AdvertisementsFair balance, the brief summary and the treatment of promotional labeling.
- eCFR — 21 CFR Part 202, Prescription Drug AdvertisingThe complete advertising part, including exemptions and enforcement provisions.
Liberty Law Library is a publication, not a law firm. This article states general rules and cites its sources; it is not advice about any particular case, and the law differs by state and changes over time.
More in Drug & Device Regulation
Premarket Notification Compared With Premarket Approval
Premarket notification under 21 U.S.C. 360(k) asks whether a device is substantially equivalent to a legally marketed predicate, meaning the same intended use and either the same technological characteristics or different ones raising no different questions of safety and effectiveness. Premarket approval under 21 U.S.C. 360e asks whether valid scientific evidence provides reasonable assurance of safety and effectiveness.
Review Board Oversight and Informed Consent Documents
Under 21 CFR Part 56 a clinical investigation may not begin until an institutional review board has approved it, applying the criteria in 56.111 covering minimized risk, favorable risk-benefit balance, equitable subject selection, informed consent, data monitoring, privacy and safeguards for vulnerable subjects. Part 50 governs consent: 50.20 sets general conditions, 50.25 lists the required elements, and 50.27 requires a signed document.
Labeling: Required Content, Format and Changes
Labeling under 21 U.S.C. 321(m) includes all written, printed or graphic matter on an article, its containers or wrappers, or accompanying it. A product is misbranded under 21 U.S.C. 352 where its labeling is false or misleading in any particular. Prescription labeling follows 21 CFR 201.56 and 201.57, over-the-counter labeling follows 201.66, and changes are made through the supplement categories in 21 CFR 314.70.